Core Insights - Xtant Medical reported a full-year 2025 revenue of $133.9 million, reflecting a 14% increase year-over-year, and achieved positive net income, adjusted EBITDA, and operating cash flow [1][3][5] Financial Performance - Fourth quarter 2025 revenue was $32.4 million, up approximately 3% compared to the prior year quarter, despite a $2.0 million revenue reduction due to the early closing of the Companion Spine transaction [2][5] - For the full year 2025, total revenue reached $134.0 million, a 14% increase from $117.3 million in 2024 [3][5] - Gross margin for the full year 2025 was 62.9%, an increase from 58.2% in 2024, attributed to sales mix and greater scale [3][6] - Net income for the full year 2025 was $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million, or a net loss of $0.12 per basic and diluted share in 2024 [3][8] - Non-GAAP adjusted EBITDA for the full year 2025 was $16.3 million, compared to an adjusted EBITDA loss of $2.3 million in 2024 [3][9] Cash Flow and Financial Position - As of December 31, 2025, the company had total cash of $17.3 million, up from $6.2 million at the end of 2024, with an additional $10.5 million received in early 2026 related to divestiture [1][11] - Net cash provided by operations for the full year 2025 was $12.5 million, compared to net cash used in operations of $11.9 million in 2024 [3][11] Strategic Developments - The company completed the sale of its non-core Coflex® and CoFix assets and international hardware businesses to Companion Spine for $21.4 million in cash, allowing it to focus on developing advanced biologics product lines [3][4] - Xtant Medical launched new products in 2025, including the next-generation synthetic bone graft, Strata™, and CollagenX™, a bovine collagen particulate product for surgical wound closure [3][4] 2026 Outlook - The company anticipates full-year 2026 revenue to be in the range of $95 million to $99 million, reflecting expected organic growth in its core higher-margin biologics business [12]

Core Insights - Xtant Medical Holdings, Inc. reported a total revenue of $33.3 million for Q3 2025, reflecting a 19% increase year-over-year, primarily driven by licensing revenue [1][3][13] - The company achieved a gross margin of 66.1%, up from 58.4% in the same quarter of the previous year, attributed to a favorable sales mix and greater scale [3][13] - Xtant Medical reiterated its full-year 2025 revenue guidance of $131-$135 million, indicating an expected growth of 11%-15% over FY24 [1][8] Financial Performance - Operating expenses decreased to $19.5 million in Q3 2025 from $20.1 million in Q3 2024, mainly due to reduced compensation and commission expenses [4][13] - The company reported a net income of $1.3 million, or $0.01 per share, compared to a net loss of $5.0 million, or $(0.04) per share, in Q3 2024 [4][13] - Non-GAAP adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of $1.0 million in the same period last year [5][13] Cash Flow and Assets - As of September 30, 2025, Xtant Medical had cash and cash equivalents of $10.6 million, an increase from $6.2 million at the end of 2024 [7][13] - The company generated $4.6 million in cash from operations in Q3 2025, compared to cash used in operations of $1.7 million in Q3 2024 [13] Strategic Developments - The anticipated sale of certain non-core spinal implant assets and international businesses to Companion Spine is expected to close by the end of 2025, allowing the company to focus on its core biologics business [2][13] - Xtant Medical launched CollagenX™, a bovine collagen particulate product aimed at enhancing surgical wound closure and promoting healing [13][21]

Core Insights - Xtant Medical Holdings, Inc. has launched CollagenX™, a bovine collagen particulate product aimed at surgical wound closure, which is designed to enhance healing, prevent dehiscence, and reduce surgical site infection risks [1][3] - The introduction of CollagenX™ is expected to complement Xtant's existing biologics portfolio and can be utilized across various surgical disciplines [2][3] Company Overview - Xtant Medical is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, emphasizing innovation and quality in its product offerings [1][3] - The company operates as a fully vertically integrated regenerative medicine firm, which allows it to maintain high standards of quality and consistency in its products [3] Market Position - The launch of CollagenX™ reflects the company's commitment to meeting the diverse needs of surgeons and patients, potentially enhancing patient outcomes [3] - Xtant Medical's mission is centered around honoring the gift of donation to improve patients' quality of life, which drives its product development and market strategies [3]